The Manufacturers Life Insurance Company Increases Stock Position in Evolus, Inc. (NASDAQ:EOLS)

The Manufacturers Life Insurance Company increased its position in Evolus, Inc. (NASDAQ:EOLS) by 36.3% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 21,825 shares of the company’s stock after acquiring an additional 5,808 shares during the period. The Manufacturers Life Insurance Company’s holdings in Evolus were worth $237,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in EOLS. Assenagon Asset Management S.A. raised its holdings in Evolus by 5,627.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company’s stock worth $10,276,000 after acquiring an additional 930,566 shares during the last quarter. Lord Abbett & CO. LLC bought a new stake in Evolus in the 1st quarter worth approximately $11,628,000. Armistice Capital LLC bought a new stake in Evolus in the 2nd quarter worth approximately $3,906,000. Zimmer Partners LP bought a new stake in Evolus in the 1st quarter worth approximately $4,200,000. Finally, BNP Paribas Financial Markets grew its position in Evolus by 84.2% in the 1st quarter. BNP Paribas Financial Markets now owns 405,931 shares of the company’s stock worth $5,683,000 after purchasing an additional 185,532 shares during the period. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on EOLS shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Evolus in a research report on Monday, September 16th. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 target price on shares of Evolus in a research report on Thursday, October 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Evolus in a research report on Friday, September 13th. Finally, Barclays lifted their target price on shares of Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th.

Evolus Trading Down 0.1 %

Shares of EOLS stock opened at $16.62 on Friday. Evolus, Inc. has a 1 year low of $7.44 and a 1 year high of $17.82. The firm has a fifty day moving average price of $15.81 and a 200-day moving average price of $13.46. The company has a debt-to-equity ratio of 6.26, a current ratio of 2.92 and a quick ratio of 2.67. The company has a market cap of $1.04 billion, a price-to-earnings ratio of -15.85 and a beta of 1.31.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings data on Wednesday, July 31st. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The firm had revenue of $66.91 million for the quarter, compared to analysts’ expectations of $65.06 million. As a group, equities analysts predict that Evolus, Inc. will post -0.64 earnings per share for the current year.

Insider Activity

In other news, CFO Sandra Beaver sold 3,276 shares of the business’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the sale, the chief financial officer now owns 148,502 shares of the company’s stock, valued at $2,224,559.96. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, CFO Sandra Beaver sold 3,276 shares of the company’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the transaction, the chief financial officer now owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $15.85, for a total transaction of $89,251.35. Following the completion of the transaction, the chief marketing officer now directly owns 82,375 shares of the company’s stock, valued at $1,305,643.75. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 6.10% of the company’s stock.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.